22108_SGLT2 Inhibition and Heart Failure: Translating the Evidence to Clinical Practice

Information on best uses of SGLT2 inhibitors for patients with HF will be disseminated through lecture, interactive case presentation, panel discussion, and question-and-answer with experts.

This program addresses the following needs of clinicians who treat patients with heart failure (HF): 1) to interpret the increasing number of analyses of subsets of data from SGLT2 inhibitor clinical trials in patients with HF with reduced ejection fraction (HFrEF) which are providing insights into their optimal utilization in HFrEF patients; 2) to indicate the renal benefits of SGLT2 inhibitors in patients with HFrEF as well as in other patients with related diseases such as those with chronic kidney disease (CKD) (up to 50% of HFrEF patients have CKD) and atherosclerotic cardiovascular disease (ASCVD), 3) to establish and expand a knowledge base of practical considerations for using SGLT2 inhibitors in HFrEF patients, and 4) to assess the emerging evidence with, and recognize ongoing clinical investigations of, SGLT2 inhibitors in patients with HF with preserved ejection fraction (HFpEF). Information on best uses of SGLT2 inhibitors for patients with HF will be disseminated through lecture, interactive case presentation, panel discussion, and question-and-answer with experts. The inperson symposium will be livestreamed to the HFSA audience who elect to attend virtually.

Login to your Account